1[1]Grigioni F, Avierinos JF, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol,2002; 40(I): 84-92.
2[2]Allessie M, Konings K, Wijffels MC. Electrophysiological mechanism of atrial fibrillation in:Dimarco JP, prystwsky EN, eds. Atrial Arrhythmias: State of the An. Future Publishing Co,1995.; 155-161.
6[6]Doval HC.Class Ⅲ antiarrhythmic agents in cardiac failure:lessons from clinical trials with a focus on the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Am J Cardiol,1999;84(9A):109R-I14R
7[7]Moller M, Torp-Pedersen CT,Kober L.Dofetilide in patients with congestive heart failure and left ventricular dysfunction:safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Monality on Dofetilide (DIAMOND) Study Group. Congest Hean Fail,2001 ;7(3):146-150
8[8]Brignole M, Menozzi C, Gasparini M, et al.An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy afier ablation and pacing therapy in patients with paroxysmal atrial fibrillation.Eur Heart J,2002 ;23(11):892-900.
9[9]Kay GN,Ellenbogen KA,Giudici M, et al.The Ablate and Pace Trial:a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation.J intervent Cardiac Electrophysiol, 1998, 2: 121-135.
10[10]Wood MA,Mahaoney BC,GN,et al.Clinical outcomes afier ablation and pacing therapy for atrial fibrillation:a meta analysis.Circulation,2000;101:1138-1144.
